Chemical Business Newsbase articles from June 2009

Chemical Business Newsbase archives from June 2009

Primary endpoint achieved in Phase III clinical trial of Epogin in chemotherapy induced anaemia.
June 30, 2009... On 30 Jun 2009, Chugai Pharmaceutical Co Ltd announced that Phase III study of the recombinant human erythropoietin Epogin Injection (epoetin beta, recombinant) achieved the primary endpoint by significantly reducing the theoretical...

Public statement on the recommendation to lift the suspension of the marketing authorisation for Optison (perflutren).
June 30, 2009... On 18 May 1998, the European Commission granted a marketing authorisation (MA) valid throughout the European Union (EU) for the medicinal product Optison (perflutren). Optison is a diagnostic agent for the enhancement of contrast effect in...

European Public Assessment Report (EPAR) Leucogen.
June 30, 2009... On 30 Jun 2009, the European Medicines Agency (EMEA) published a European Public Assessment Report (EPAR) for Leucogen (veterinary vaccine). There are questions and answers covering: What is LEUCOGEN?, What is LEUCOGEN used for?, How does...

Inventory of herbal substances for assessment - alphabetical order. [1 table in original article].
June 30, 2009... On 30 Jun 2009, the European Medicines Agency (EMEA) published an inventory of herbal substances for assessment. There is a fourteen page table, with data categorised as: Total priority HMPC 2005, Later request by external IP, Status (HMPC...

Committee for Medicinal Products for Veterinary Use European public MRL assessment report (EPMAR): Cyfluthrin: Extrapolation to caprine species.
June 30, 2009... On 16 Jun 2008, the European Commission adopted a Regulation establishing maximum residue limits for cyfluthrin in caprine species, valid throughout the European Union. These maximum residue limits were based on the favourable opinion and the...

Committee for Medicinal Products for Veterinary Use European public MRL assessment report (EPMAR): Monepantel (ovine and caprine).
June 30, 2009... On 8 Jun 2009 the European Commission adopted a Regulation establishing maximum residue limits for monepantel in ovine and caprine species, valid throughout the European Union. These maximum residue limits were based on the favourable opinion...

Committee for Medicinal Products for Veterinary Use European public MRL assessment report (EPMAR): Tiludronic acid (Extension to poultry species).
June 30, 2009... On 9 Jun 2009 the European Commission adopted a Regulation establishing maximum residue limits for tiludronic acid (in the form of disodium salt) in poultry, valid throughout the European Union. These maximum residue limits were based on the...

Organ-specific warnings; internal analgesic, antipyretic, and antirheumatic drug products for over-the-counter human use; final monograph; corrections.
June 30, 2009... The US Food and Drug Administration (FDA) is correcting a final rule that appeared in the Federal Register of 29 Apr 2009. The document requires important new organ-specific warnings and related labelling for over-the-counter (OTC) internal...

Manufacturer of controlled substances; notice of application (Chattem Chemicals Inc).
June 30, 2009... Chattem Chemicals Inc, 3801 St Elmo Avenue, Building 18, Chattanooga, TN, USA, made application by renewal to the US Drug Enforcement Administration (DEA) on 8 May 2009 as a bulk manufacturer of the basic classes of controlled substances...

Manufacturer of controlled substances; notice of registration (Johnson Matthey Inc).
June 30, 2009... Johnson Matthey Inc, Custom Pharmaceuticals Department, 2003 Nolte Drive, West Deptford, NJ, USA, made application by letter to the US Drug Enforcement Administration (DEA) on 29 Sep 2008 to be registered as a bulk manufacturer of gamma...

Manufacturer of controlled substances; notice of registration (Norac Inc).
June 30, 2009... Norac Inc, 405 S Motor Avenue, PO Box 577, Azusa, CA, USA, made application by letter to the US Drug Enforcement Administration (DEA) on 27 Jun 2008 for registration as a bulk manufacturer of gamma hydroxybutyric acid (GHB), a basic class of...

Importer of controlled substances; notice of registration (Sigma Aldrich Manufacturing LLC).
June 30, 2009... Sigma Aldrich Manufacturing LLC, 3500 Dekalb Street, St Louis, MO, USA, made application by renewal to the US Drug Enforcement Administration (DEA) on 2 Mar 2009 to be registered as an importer of the basic classes of controlled substances...

Importer of controlled substances; notice of registration (Lipomed Inc).
June 30, 2009... Lipomed Inc, One Broadway, Cambridge, MA, USA, made application by renewal to the US Drug Enforcement Administration (DEA) on 9 Apr 2009 to be registered as an importer of the basic classes of 58 controlled substances listed in schedules I...

Biological E nod for anthrax vaccine.
June 30, 2009... The Drug Controller General of India has granted registration to Biological E Ltd for the company's Biothrax (anthrax vaccine). The vaccine will be marketed by Emergent BioSolutions in India. Biothrax is the only FDA-licensed vaccine for...

Bheema Cements to pay 12% dividend for 2008-2009.
June 30, 2009... The Board of the Hyderabad-based Bheema Cements Ltd has recommended a dividend of 12% for 2008-2009.

Finolex 4Q 2008-2009 net profit rises on fall in input costs.
June 30, 2009... Finolex Industries Ltd has posted a profit-after-tax (PAT) of Rup 33 crores on a turnover of Rup 422.87 crores for 4Q 2008-2009 (PAT of Rup 1.21 crores on a turnover of Rup 501 crores for 4Q 2007-2008). The increase in profit is attributed to...

Orchid in red over forex, derivatives losses.
June 30, 2009... Pharma firm Orchid Chemicals and Pharmaceuticals has incurred a net loss of Rup 52 crores on a turnover of Rup 115 crores for 2008-2009 (net profit of Rup 184 crores on a turnover of Rup 119 crores in 2007-2008). The loss is attributed...

Gujarat Alkalies and Chemicals: Results for 4Q 2008-2009.
June 30, 2009... Chemicals manufacturer Gujarat Alkalies and Chemicals Ltd has reported a net profit of Rup 2158 lakhs on net sales/income from operations of Rup 33,899 lakhs for 4Q ended Mar 2009 (net profit of Rup 1835 lakhs on net sales/income from...

BASF lowers PS capacity by 15%.
June 30, 2009... BASF is to permanently close a PS plant in Ludwigshafen on 30 Jun 2009. Capacity in Europe will thus fall by 15% to 540,000 tonnes/y. Some 80,000 tonnes/y less will be produced. PS will still be produced in Ludwisgshafen but mainly for the...

Lanxess delays production start and utilizes time to use new technology,.
June 30, 2009... Because of the economic crisis, Lanxess has postponed the construction of a butyl rubber plant in Singapore. The company will use the time to develop a new manufacturing process for mass production. Production was to start in 2012 but is now...

New and generic drug approvals: Feraheme Injection, Amag Pharms.
June 30, 2009... On 30 Jun 2009, the US Food and Drug Administration announced approval of NDA 022180 for Feraheme Injection. The product contains ferumoxytol at 30mg/ml, is manufactured by Amag Pharms Inc, and is prescription only. There are no therapeutic...

New and generic drug approvals: Olanzapine Oral Tablet, Dr Reddy's Lab.
June 30, 2009... On 30 Jun 2009, the US Food and Drug Administration announced the tentative approval of ANDA 076133 for Olanzapine Oral Tablet. The product contains olanzapine at 15mg or 20mg and is manufactured by Dr Reddy's Lab Inc. There are no...

New and generic drug approvals: Azelastine Hydrochloride Ophthalmic Solution, Sun Pharm Inds.
June 30, 2009... On 30 Jun 2009, the US Food and Drug Administration announced the tentative approval of ANDA 078738 for Azelastine Hydrochloride Ophthalmic Solution. The product contains azelastine hydrochloride at 0.05% and is manufactured by Sun Pharm Inds...

New and generic drug approvals: Alfuzosin Hydrochloride Extended Release Oral Tablet, Invagen Pharms.
June 30, 2009... On 30 Jun 2009, the US Food and Drug Administration announced the tentative approval of ANDA 090284 for Alfuzosin Hydrochloride Extended Release Oral Tablet. The product contains alfuzosin hydrochloride at 10mg and is manufactured by Invagen...

Chelsea Therapeutics achieves target enrolment in Phase III trial of Droxidopa in neurogenic orthostatic hypotension.
June 30, 2009... Chelsea Therapeutics International Ltd (Chelsea) has successfully reached its target enrolment of 82 patients for Study 302, the first of two pivotal Phase III clinical trials in Chelsea's registration programme of Droxidopa for the treatment...

TapImmune Inc announces corporate restructuring.
June 30, 2009... TapImmune Inc announces the appointment of Dr Glynn Wilson as TapImmune's new Executive Chairman as part of an overall corporate restructuring plan. Dr Wilson succeeds Alan Lindsay whom TapImmune Inc thanks for his service and contributions...

Momenta Pharmaceuticals announces top-line results from the M118 EMINENCE trial.
June 30, 2009... Momenta Pharmaceuticals Inc (Momenta) announced top-line results from the EMINENCE (Evaluation of M118 in Percutaneous Coronary Intervention) Phase II multi-centre study of the intravenous formulation of M118. EMINENCE was designed to...

Warnex Inc's Medical Laboratories division obtains ISO 15189 accreditation.
June 30, 2009... Warnex Inc announced that its Medical Laboratories division has obtained ISO 15189:2007 accreditation by the Standards Council of Canada (SCC). This accreditation is an international standard for quality management systems for medical testing...

Vical H1 influenza vaccine delivers robust pre-clinical results with 100% response.
June 30, 2009... Vical Inc announced that the company's vaccine against A/H1N1 pandemic influenza (swine flu) produced robust immune responses well above the accepted protection threshold in 100% of vaccinated mice and rabbits after a standard two-dose...

Caliper Life Sciences introduces Staccato Protein Workstation for automated protein sample preparation and analysis.
June 30, 2009... Caliper Life Sciences Inc (Caliper) launched the Staccato Protein Workstation to specifically address bottlenecks in the characterization of biological therapeutics and biogenerics. With a goal of assuring the quality of therapeutic proteins...

Antitope and Vascular Pharmaceuticals enter into a antibody research agreement.
June 30, 2009... Antitope, a privately held biotechnology company, announced a research agreement with Vascular Pharmaceuticals Inc for the generation of therapeutic antibodies for treatment of vascular disease. The agreement brings together Vascular...

Vivalis raises its 2009 commercial targets.
June 30, 2009... Vivalis announced the signature of a new research agreement with a company whose name remains undisclosed for the production of monoclonal antibodies on its EB66 cell line platform. Since 1 Jan 2009, Vivalis has signed seven new commercial...

Thermo Fisher Scientific launches new Online SPE clean-up system.
June 30, 2009... Thermo Fisher Scientific Inc launched its Thermo Scientific HyperSep Online SPE Products. This comprehensive range of solid phase extraction products has been designed to improve laboratory efficiency, enabling fast and effective clean-up and...

EU: Pfizer promising changes to Wyeth bid.
June 30, 2009... US drug maker Pfizer Inc has promised to make changes to its takeover of rival Wyeth in order to win European Union regulatory approval for the deal. The European Commission gave no details of any potential selloffs or commitments put...

Sanofi-Aventis (France) remodels R&D, eight sites close, no forced layoffs.
June 30, 2009... Sanofi-aventis presented its new Research and Development model project. The model, which aims to transform R&D and increase innovation, is the first pillar of the Group's new strategy which was presented in Feb 2009 by Christopher A...

Drug companies defend acetaminophen as FDA considers restrictions.
June 30, 2009... Worried about possible liver damage from overuse and more than 20,000 accidental overdoses, an FDA advisory committee is considering ways to reduce the risk from acetaminophen, one of the nation's most popular over-the-counter drugs. A joint...

New cancer treatment shows promise in testing.
June 30, 2009... A new method of attacking cancer cells, developed by researchers in Australia, has proved surprisingly effective in animal tests. The method is intended to sidestep two major drawbacks of standard chemotherapy: The treatment's lack of...

Maxygen announces joint venture with Astellas to develop protein pharmaceuticals.
June 30, 2009... Maxygen Inc announced that Astellas Pharma Inc (Astellas) and Maxygen have executed an agreement to establish a joint venture focused on the discovery, research and development of multiple protein pharmaceutical programmes, including...

FDA Finds E coli in sample from Nestle's factory.
June 30, 2009... On 29 Jun 2009, The FDA announced that E coli 0157:H7 contamination has been confirmed in Nestle Toll House cookie dough. A sample taken from Nestle's Danville, VA plant tested positive for the presence of the E coli bacteria. The link...

FDA approves Feraheme to treat iron deficiency anaemia in adult chronic kidney disease patients.
June 30, 2009... Amag Pharmaceuticals Inc announced that the US Food and Drug Administration (FDA) has granted marketing approval for Feraheme (ferumoxytol) Injection for intravenous (IV) use as an iron replacement therapy for the treatment of iron deficiency...

Pfizer discontinues Phase III trial of Sutent in metastatic colorectal cancer.
June 30, 2009... Pfizer Inc announced the discontinuation of the SUN 1122 Phase III trial that evaluated Sutent (sunitinib malate) plus FOLFIRI (irinotecan plus infusional 5-fluorouracil and leucovorin) versus FOLFIRI alone for the first-line treatment of...

Retractable Technologies Inc acts to reduce annual operating expenses by $6 M.
June 30, 2009... Retractable Technologies Inc (Retractable) continues to experience significant barriers against its efforts to establish access for sales of its products. With limited access to capital markets, it has determined that in the interest of the...

ViraCor Laboratories and IBT Laboratories merging to create unique speciality diagnostics company.
June 30, 2009... ViraCor Laboratories (ViraCor) and IBT Laboratories (IBT) are merging to create a new speciality diagnostics laboratory. Uniting the strengths of ViraCor and IBT, the new company has a strong research and development (R&D) infrastructure and...

Aushon technology chosen for small molecule microarray research.
June 30, 2009... Aushon BioSystems Inc (Aushon) recently announced that the Eli and Edythe L Broad Institute of MIT and Harvard will utilize Aushon's 2470 Arrayer technology for their small molecule microarray research. The 2470 Arrayer has been installed in...

Genetic hair loss test to be introduced in Dominican Republic through HairDX distribution agreement.
June 30, 2009... Men and women in the Dominican Republic will soon have access to genetic tests for predicting the risk of male or female hair loss thanks to a distribution agreement announced by pharmacogenomics research and development innovator...

KAI Pharmaceuticals acquires patents from Progen, broadening KAI's intellectual property estate covering peptide-based therapies.
June 30, 2009... KAI Pharmaceuticals Inc (KAI), announced the acquisition of an extensive collection of issued and pending patents from Progen Pharmaceuticals Ltd (Progen), a globally focused biotechnology company. The patents claim compositions and methods...

Rubicon Genomics introduces PicoPlex Single Cell Whole Genome Amplification Kit for pre-implantation genetic diagnostics and stem cell and cancer cell research.
June 30, 2009... Rubicon Genomics Inc announced on 30 Jun 2009 the release of its PicoPlex Single Cell Whole Genome Amplification (WGA) kita more rapid, accurate and reproducible method for amplifying single genomes than current technologies. This product...

Saladax Biomedical Inc signs agreement with Stockholm's Karolinska University Hospital.
June 30, 2009... Saladax Biomedical Inc (Saladax) has signed an agreement with the Karolinska University Hospital (Karolinska), of Stockholm, Sweden. Karolinska will provide clinical laboratory testing for the Saladax 5-Fluorouracil (5-FU) Assay based at...

New nutritional supplement BioShield-Radiation first to offer radiation protection in pill form.
June 30, 2009... After a series of comprehensive research studies and a governmental research initiative, a respected team of radiation biologists and antioxidant scientists at Premier Micronutrient Corp has developed BioShield-Radiation - a patented...

Oragenics announces $5 M in new financing, and changes in its board of directors and management.
June 30, 2009... Oragenics Inc has closed an investment contract with the Koski Family Ltd Partnership (Koski Family) to provide new capital for continuing operations. Pursuant to this contract, the Koski Family agreed to invest $4 M in equity in exchange for...

New expanded Atlantis patient-specific abutment compatibility and material option for Straumann implants.
June 30, 2009... Astra Tech is pleased to announce the availability of expanded Atlantis abutment options for Straumann implants. Following the recent launch of Atlantis abutments in titanium and gold-shaded titanium for Straumann Bone Level 4.1 and 4.8...

Applied Biosystems Salmonella detection kit assists efforts to protect food supply.
June 30, 2009... Applied Biosystems, part of Life Technologies Corp, announced the certification of its TaqMan Salmonella enterica Detection Kit for the identification of Salmonella in peanut butter through the new Emergency Response Validation programme of...

New IvyClear Poison Ivy Wash with dual-action formula relieves the itch, soothes and removes oils from the skin resulting from contact with poison ivy, poison oak and poison sumac.
June 30, 2009... Just in time for peak outdoors season comes IvyClear Poison Ivy Wash, the first dual-acting, topical lotion that removes the rash-creating oils from contact with poison ivy, oak and sumac, relieves itching and soothes skin. The oily culprit...

CytRx files report with the FDA in response to the partial clinical hold on its Phase IIb arimoclomol ALS trial.
June 30, 2009... CytRx Corp has filed a report with the US Food and Drug Administrations (FDA) in response to the Agency's partial clinical hold on the company's Phase IIb efficacy clinical trial with its molecular chaperone regulator drug candidate...

Pozen submits new drug application for Vimovo (PN 400).
June 30, 2009... Pozen Inc announced the submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for the marketing approval of Vimovo (PN 400), the combination of enteric coated (EC) naproxen and immediate release esomeprazole....

Gore receives FDA approval for modification of Gore Viabahn endoprosthesis.
June 30, 2009... WL Gore & Associates (Gore) announced that it has received approval from the US Food and Drug Administration (FDA) for a manufacturing change to the Gore Viabahn Endoprosthesis. The modification is a result of the precision laser trimming...

Medarex to receive milestone payment for the approval of Ilaris for the treatment of cryopyrin-associated periodic syndrome.
June 30, 2009... Medarex Inc announced it will receive a milestone payment of an undisclosed amount from Novartis Pharma AG (Novartis), in connection with the marketing approval from the US Food and Drug Administration (FDA), to market Ilaris (canakinumab,...

Collegium Pharmaceutical announces the sale of AllerNaze to Lupin.
June 30, 2009... Collegium Pharmaceutical Inc announced that Lupin has acquired all worldwide rights to AllerNaze (triamcinolone acetonide, USP) Nasal Spray, 50 mcg. AllerNaze is an aqueous based intranasal steroid (INS) product indicated for the once daily...

BioScrip commences patient enrolment in Teva Neuroscience Therapy Optimization in Multiple Sclerosis (Tops MS) research study.
June 30, 2009... BioScrip Inc announced that Teva Neuroscience tapped BioScrip Speciality Pharmacy as one of several national research study participants in one of the most comprehensive MS research studies announced to date. TOP MS is a new research study...

BioSante Pharmaceuticals and Cell Genesys sign definitive merger agreement.
June 30, 2009... BioSante Pharmaceuticals Inc (BioSante) and Cell Genesys have entered into a definitive merger agreement by which the companies will merge in an all-stock transaction, with BioSante as the surviving company. Under the terms of the merger...

GE Healthcare and Geron announce exclusive global agreement to commercialize stem cell drug discovery technologies.
June 30, 2009... GE Healthcare and Geron Corp have entered into a global exclusive licence and alliance agreement to develop and commercialize cellular assay products derived from human embryonic stem cells (hESCs) for use in drug discovery, development and...

Compugen reports sale of a portion of its Evogene holdings.
June 30, 2009... Compugen Ltd has received about $3.6 M from the private sale of 1 M Evogene shares to a single purchaser. The funds generated from this transaction are expected to be used by Compugen for general corporate purposes through mid 2010. After...

Oxea announces price increases in Europe.
June 30, 2009... Oxea will increase off-list prices on the following products effective 1 Jul 2009, or as contracts allow. This increase is in addition to any previously announced mid quarter increase during 2Q 2009. Price increase for i/n Butyl Acetate is...

Orexo announces that Abstral is ready for launch in France.
June 30, 2009... Orexo announced that ProStrakan Group plc, Orexo's partner for Abstral in Europe and North America, confirms that it has completed the reimbursement pricing process with the French authorities for its pan-European breakthrough cancer pain...

Inovio Biomedical, National Microbiology Laboratory, and University of Pennsylvania to evaluate candidate DNA vaccines against swine influenza A (H1N1).
June 30, 2009... Inovio Biomedical Corp (Inovio) has established a new collaboration with the National Microbiology Laboratory of the Public Health Agency of Canada and the University of Pennsylvania to further evaluate Inovio DNA vaccine candidates against...

Ellis Energy Investments acquires Pyron Solar.
June 30, 2009... Ellis Energy Investments Inc has acquired the assets of Pyron Solar Inc. Pyron Solar is the manufacturer of the Pyron Solar Triad, the leading CPV Power Generator for utility scale installations. The company uses a patented and powerful solar...

KMP completes first commercial shipment of biodiesel in US on plantation pipe line.
June 30, 2009... Kinder Morgan Energy Partners LP announced that Plantation Pipe Line Co is the first pipeline company in the US to transport biodiesel for commercial purposes. Plantation Pipe Line completed the first transmarket commercial shipment of...

Energy revolution embraces all new technology.
June 30, 2009... Alkane Inc announced that its flagship product, alternative diesel fuel additive, Monster Diesel, is 'going digital', launching an entirely renovated interactive Website and signing on with social media tools Twitter, Facebook, and MySpace....

Semilab continues to build metrology portfolio with acquisition of SDI.
June 30, 2009... Semilab has acquired Semiconductor Diagnostics Inc (SDI). The Tampa, FL-based company is a leader in non-contact measurement solutions for wafer, IC and solar manufacturers. SDI will operate as part of the newly announced Semilab USA. Semilab...

Saudi Aramco and ConocoPhillips re-launch bidding process for Yanbu project.
June 30, 2009... The Saudi Arabian Oil Co and ConocoPhillips announced the re-launch of the bidding process for the construction of the planned 400,000 bbl/day export refinery at the Yanbu Industrial City, in the Kingdom of Saudi Arabia. The full-conversion...

QuantaSol unveils 28.3% efficient single-junction solar cell.
June 30, 2009... QuantaSol Ltd has developed what it believes to be the most efficient single junction solar cell ever manufactured. Developed in just two years, QuantaSol's single-junction device has been independently tested by Fraunhofer ISE as achieving...

Optimata to collaborate with Teva Pharmaceutical Industries Ltd on clinical development of solid tumour cancer drugs.
June 30, 2009... Optimata Ltd has signed a collaboration agreement with Teva Pharmaceutical Industries Ltd focused on clinical development of drug candidates for solid tumour cancers. The agreement is intended to efficiently rescue and redirect the clinical...

Committee for Advanced Therapies adopts first classification recommendation for an advanced therapy medicinal product.
June 30, 2009... The European Medicines Agency's (EMEA) Committee for Advanced Therapies (CAT) has adopted its first scientific recommendation on classification of an advanced therapy medicinal product. Advanced therapy medicinal products are medicines for...

Committee for Advanced Therapies (CAT) Jun 2009 meeting, monthly report: Initial applications for marketing authorisation.
June 30, 2009... At its meeting of 18 to 19 Jun 2009, the European Medicines Agency's (EMEA) Committee for Advanced Therapies (CAT) adopted one draft positive opinion by majority on an initial marketing authorisation application (in accordance with Regulation...

Committee for Advanced Therapies (CAT) Jun 2009 meeting, monthly report: Scientific recommendation on advanced therapy classification.
June 30, 2009... At its meeting of 18 to 19 Jun 2009, the European Medicines Agency's (EMEA) Committee for Advanced Therapies (CAT) adopted one scientific recommendation on the classification of an advanced therapy medicinal product (ATMP) The product,...

Committee for Medicinal Products for Veterinary Use European public MRL assessment report (EPMAR): Iron fumarate.
June 30, 2009... On 9 Jun 2009 the European Commission adopted a Regulation establishing maximum residue limits for iron fumarate in all food producing species, valid throughout the European Union. These maximum residue limits were based on the favourable...

GeoPharma announces 4Q and year 2008-2009 end results.
June 30, 2009... GeoPharma Inc announced its results for 4Q and year ended Mar 2009. Total revenues were $63,020,060 for 2008-2009 representing an increase of approximately 14.6% versus 2007-2008. Revenues for 4Q 2008-2009 were $13,842,033. Pharmaceutical...

Green Planet Bioengineering delivers strong 1Q 2009 results.
June 30, 2009... Green Planet Bioengineering Co Ltd (Green Planet) reports record 1Q ended Mar 2009 results. The 1Q 2009 revenue was up 5% to $2,297,621 ($2,192,799 for 1Q 2008). EBITDA (earnings before interest, taxes, depreciation and amortization) was...

ReNeuron preliminary results for the year ended Mar 2009.
June 30, 2009... Loss for year ended Mar 2009 reduced to GBP 3.7 M (loss of GBP 6.6 M in year ended Mar 2008). ReNeuron is strongly positioned to build on the achievements as it transitions into a leading clinical-stage stem cell development business.

Brazil miner Vale to lay off up to 300 workers in Jul.
June 30, 2009... Brazilian mining giant Vale will lay off 200 to 300 workers in Jul 2009, bringing to nearly 2,000 the number of job cuts since the deterioration of the global financial crisis in Nov 2008. According to Oliveira, the president of the Metabase...

Brazil aviation fuel price raised by 12.23% Snea.
June 30, 2009... Brazilian oil company Petrobras will raise the price of aviation fuel by 12.23% on 1 Jul 2009, the National Air Companies Association (SNEA) said. Considering this hike, the price of aviation fuel has dropped an accumulated 16.72% in 2009.

Xiameter Brand launches expanded online marketplace for silicone-based products.
June 30, 2009... The Xiameter web-enabled marketplace from Dow Corning Corp launched an expanded business model and new website to provide more products, better functionality, and an easier method to order silicone-based products. The Xiameter business...

FDA inspects Hovione's API manufacturing plant in Macau.
June 30, 2009... Hovione's API plant in Macau has just successfully passed a pre-approval inspection by FDA. The inspection, carried out the investigator of New York District office in Buffalo and a Chemist from California District started on 22 Jun 2009 and...

Particle Sciences and Microfluidics collaborate to share formulation and nanotechnology expertise for pharmaceutical drug product development, analysis and commercialisation.
June 30, 2009... Microfluidics and Particle Sciences Inc have formed a strategic alliance to help biopharmaceutical companies leverage the most advanced and reliable nanotechnology and formulation methods available to develop, analyze and commercialize active...